Yield10 Story

<div class='circular--portrait' style='background:#169D0B;color: #E6E6FA;font-size:4em;'>YB</div>
YTEN -- USA Stock  

USD 14.44  0.09  0.63%

Yield10 Bioscience Market Capitalization is quite stable at the moment as compared to the past year. The company's current value of Market Capitalization is estimated at 49.68 Million. Tangible Asset Value is expected to rise to about 12.7 M this year, although the value of Net Income Per Employee will most likely fall to (470.5 K). In this article, we will outline Yield10 Bioscience as a potential position in addition to your existing holdings. We will inspect why it could be a game-changer for Yield10 Bioscience institutional investors.
Published over a month ago
View all stories for Yield10 Bioscience | View All Stories
Are Yield10 (NASDAQ:YTEN) institutional investors starting to hold back?
About 30.0% of Yield10 Bioscience outstanding shares are owned by insiders. Insiders ownership of Yield10 Bioscience refers to the amount of Yield10 Bioscience equity owned by Yield10 officers, directors, relatives of the leadership team, or anyone who has access to private information before it's made available to the public. Check out our latest analysis of Yield10, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Yield10 Bioscience. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Yield10 Bioscience

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Yield10 Bioscience's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Yield10 Bioscience in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Yield10 Bioscience. Your research has to be compared to or analyzed against Yield10 Bioscience's peers to derive any actionable benefits. When done correctly, Yield10 Bioscience's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Yield10 Bioscience.

How important is Yield10 Bioscience's Liquidity

Yield10 Bioscience financial leverage refers to using borrowed capital as a funding source to finance Yield10 Bioscience ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Yield10 Bioscience financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Yield10 Bioscience's total debt and its cash.

How Yield10 utilizes its cash?

To perform a cash flow analysis of Yield10 Bioscience, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Yield10 Bioscience is receiving and how much cash it distributes out in a given period. The Yield10 Bioscience cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Yield10 Bioscience Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (14.27 Million)

Yield10 Bioscience exotic insider transaction detected

Legal trades by Yield10 Bioscience insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Yield10 insider trading alert for general transaction of common stock by Kristi Snell, VP Research & CSO, on 16th of February 2021. This event was filed by Yield10 Bioscience Inc with SEC on 2021-02-16. Statement of changes in beneficial ownership - SEC Form 4. Kristi Snell currently serves as chief science officer, vice president - research of Yield10 Bioscience [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Yield10 Bioscience valued adequately by the market?

The latest price rise of Yield10 Bioscience may raise some interest from institutional investors as it is trading at a share price of 15.93 on 786,513 in trading volume. The company directors and management may have good odds in positioning the company resources to exploit market volatility in February. The stock standard deviation of daily returns for 30 days investing horizon is currently 11.25. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Yield10 Bioscience partners.

Returns Breakdown

Return on Investment(120.99)
Return on Assets(67.79)
Return on Equity(97.28)
Return Capital(12.43)
Return on Sales(9.31)

Are Yield10 Bioscience technical ratios showing a collapse?

Potential upside is down to 10.82. It may entail a possible volatility slide. Yield10 Bioscience is displaying above-average volatility over the selected time horizon. Investors should scrutinize Yield10 Bioscience independently to ensure intended market timing strategies are aligned with expectations about Yield10 Bioscience volatility.

The Current Takeaway on Yield10 Bioscience Investment

Whereas some other entities under the agricultural inputs industry are still a bit expensive, Yield10 Bioscience may offer a potential longer-term growth to institutional investors. On the whole, as of the 22nd of January 2021, we believe that Yield10 Bioscience is currently undervalued with very high chance of financial distress in the next two years. However, our actual 30 days 'Buy-vs-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Yield10 Bioscience. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com